Longitudinal Studies of Patient With FPDMM
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT03854318|
Recruitment Status : Recruiting
First Posted : February 26, 2019
Last Update Posted : March 22, 2019
|Condition or disease|
|Inherited Hematological Diseases Rare Diseases FPDMM|
|Study Type :||Observational|
|Estimated Enrollment :||1000 participants|
|Official Title:||Longitudinal Studies of Patient With FPDMM|
|Estimated Study Start Date :||March 27, 2019|
|Estimated Primary Completion Date :||December 31, 2028|
|Estimated Study Completion Date :||December 31, 2028|
Patients enrolled in this protocol will have been referred with a known or suspected RUNX1mutation.
Direct family members of enrolled patients will be asked to enroll in the study to providespecimens for genetic testing, next-generation sequencing, and other related studies.
- Natural History [ Time Frame: Ongoing ]This protocol continues the decades-long tradition of identifying and examining patients with rare genetic diseases and characterizingthe natural history.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03854318
|Contact: Paul Liu, M.D.||(301) email@example.com|
|United States, Maryland|
|National Institutes of Health Clinical Center||Recruiting|
|Bethesda, Maryland, United States, 20892|
|Principal Investigator:||Paul Liu, M.D.||National Human Genome Research Institute (NHGRI)|